Frankfurt - Delayed Quote EUR
Telix Pharmaceuticals Limited (T3X.F)
16.89
+1.09
+(6.93%)
At close: 4:56:36 PM GMT+2
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 0 | 0 |
| Sales | -- | 0 |
| Net Shares Purchased (Sold) | 0 | 0 |
| Total Insider Shares Held | 68.65M | -- |
| % Net Shares Purchased (Sold) | -- | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| Olson (Tiffany) Independent Non-Executive Director | Purchase at price 17.88 per share. | Direct | 202,321 | Mar 5, 2025 |
| McDonald (Marie) Independent Non-Executive Director | Purchase at price 17.04 per share. | Direct | 63,389 | Mar 5, 2025 |
| Behrenbruch (Christian P. Ph.D.) Chief Executive Officer | Sale at price 18.39 per share. | Direct | 36,774,600 | Feb 27, 2025 |
| McCann (Harry Kevin) Chairman of the Board | Sale at price 18.97 per share. | Direct | 569,010 | Feb 27, 2025 |
| Kluge (Andreas) Former | -- | Direct | -- | Oct 17, 2024 |
| Behrenbruch (Christian P. Ph.D.) Chief Executive Officer | -- | Direct | -- | May 17, 2024 |
| Cade (David) Divisional Officer | -- | Direct | -- | May 17, 2024 |
| Valeix (R) Chief Commercial Officer | -- | Direct | -- | May 17, 2024 |
| Behrenbruch (Christian P. Ph.D.) Chief Executive Officer | Other at price 7.23 per share. | Direct | 1,107,884 | Jan 18, 2024 |
Related Tickers
ASPHF Ascentage Pharma Group International
5.83
-9.69%
BEAM.MX Beam Therapeutics Inc.
390.00
+4.18%
ADAG Adagene Inc.
1.3900
-2.80%
AAPG Ascentage Pharma Group Internat
25.50
+6.69%
BCTXW BriaCell Therapeutics Corp.
0.1706
+36.48%
SER Serina Therapeutics, Inc.
6.09
+5.36%
RNTX Rein Therapeutics Inc.
1.8300
+0.55%
MBX MBX Biosciences, Inc.
9.27
+3.11%
DSGN Design Therapeutics, Inc.
4.2400
+4.18%
BCAX Bicara Therapeutics Inc.
15.63
+0.77%